| Literature DB >> 20698993 |
Abstract
BACKGROUND: Several cis-acting regulatory sequences functioning at the level of mRNA or nascent peptide and specifically influencing transcription or translation have been described. These regulatory elements often respond to specific chemicals.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20698993 PMCID: PMC2928234 DOI: 10.1186/1471-2199-11-56
Source DB: PubMed Journal: BMC Mol Biol ISSN: 1471-2199 Impact factor: 2.946
The activities of the constructs isolated as measured in three reporter systems.
| E1 | Asp His Tyr Ser Arg Ile Val | 2.02 (±0.11) | 1.46 (±0.10) | ND |
| E2 | Val Ile Gly Arg Asn Ser Phe | 1.70 (±0.09) | 1.85 (±0.04) | ND |
| E3 | Gly Thr Ser Leu Gly Arg Gly | 1.66 (±0.09) | 1.61 (±0.08) | ND |
| E4 | Leu Gly Ile Arg Ser Gly Tyr | 1.63 (±0.11) | 2.04 (±0.03) | 1.62 (±0.12) |
| E5 | Ile Ser Val Trp Leu Val Ala | 1.58 (±0.16) | 1.95 (±0.05) | 1.55 (±0.01) |
| E6 | Gly Trp His Leu Arg Leu Val | 1.56 (±0.14) | 1.95 (±0.06) | 1.33 (±0.05) |
| E7 | Val Gly Leu Phe Ala Asn Gly | 1.54 (±0.12) | 1.53 (±0.08) | ND |
| E8 | Ala Ser Ser Val Ser His Leu | 1.53 (±0.21) | 1.73 (±0.12) | ND |
| E9 | Phe Ile Leu Ser Ile Ser Leu | 1.48 (±0.17) | 1.63 (±0.06) | ND |
| E10 | Leu Val Leu Cys Asn Leu Leu | 1.46 (±0.07) | 1.41 (±0.04) | ND |
| control | - | 1.06 (±0.13) | 1.26 (±0.06) | 1.15 (±0.04) |
| C1 | Gln Glu Arg Ala Thr Gly Val | 3.06 (±0.18) | 2.46 (±0.06) | 1.95 (±0.02) |
| C2 | Arg Gly Gly Phe Ser Asn Glu | 2.89 (±0.06) | 1.73 (±0.08) | ND |
| C3 | Glu Asn Ala Pro Ser Tyr Asp | 2.62 (±0.10) | 2.00 (±0.14) | ND |
| C4 | Ser Ser Gly Ala Phe Gly Thr | 2.49 (±0.04) | 1.74 (±0.12) | ND |
| C5 | Arg Val Pro Pro Arg Arg Cys | 2.35 (±0.14) | 2.08 (±0.09) | ND |
| C6 | Phe Leu Glu Val Gly Cys Ser | 2.32 (±0.11) | 2.40 (±0.03) | 3.11 (±0.02) |
| C7 | Gly Arg Gln Val Gly Arg Val | 2.14 (±0.10) | 1.72 (±0.11) | ND |
| C8 | Ser Val Cys Cys Phe Val Phe | 2.01 (±0.08) | 2.05 (±0.13) | ND |
| C9 | Cys Trp Gly Ile Asp Met Ala | 2.00 (±0.15) | 2.17 (±0.04) | 1.91 (±0.05) |
| C10 | Lys Thr Tyr Val Gly Lys Ile | 1.93 (±0.12) | 1.95 (±0.07) | ND |
| control | - | 1.41 (±0.06) | 1.43 (±0.12) | 1.43 (±0.08) |
| T1 | Asn Leu Glu Ser Val Leu Ser | 2.03 (±0.14) | 2.36 (±0.11) | 0.46 (±0.02) |
| T2 | Arg Val Arg Asp Val Phe Tyr | 1.78 (±0.05) | 1.53 (±0.10) | ND |
| T3 | Arg Gly Glu Gly Trp Gly Leu | 1.67 (±0.15) | 1.63 (±0.14) | ND |
| T4 | Gly Arg Gly Arg Cys Val Ser | 1.65 (±0.06) | 2.14 (±0.10) | 0.70 (±0.21) |
| T5 | Ser Ala Glu Ala Phe Arg Ala | 1.58 (±0.08) | 1.51 (±0.07) | ND |
| T6 | Ile Leu Met Leu Arg Arg Ser | 1.56 (±0.13) | 1.62 (±0.11) | ND |
| T7 | Gly Gly Ser Ala Phe Ile Glu | 1.45 (±0.13) | 1.53 (±0.04) | ND |
| T8 | Glu Cys Gln Ser Arg His Met | 1.37 (±0.10) | 1.67 (±0.08) | ND |
| T9 | Ile Ser Ile Met Arg Arg Cys | 1.21 (±0.08) | 1.85 (±0.06) | 0.81 (±0.10) |
| T10 | Pro Ser Ala Arg Ile His Arg | 1.20 (±0.11) | 1.38 (±0.13) | ND |
| control | - | 1.11 (±0.13) | 1.54 (±0.03) | 0.91 (±0.05) |
| M1 | Glu Arg Thr Tyr Ile Met Tyr | 2.35 (±0.13) | 0.99 (±0.08) | 1.34 (±0.07) |
| M2 | Ser Trp Gly Leu Ala Ala Lys | 2.24 (±0.08) | 0.73 (±0.09) | 1.39 (±0.06) |
| M3 | Arg Ala Asp Arg Phe Lys Phe | 2.14 (±0.04) | 1.10 (±0.01) | 1.86 (±0.15) |
| M4 | Lys Tyr Gln Leu Leu Ile Cys | 1.90 (±0.12) | 1.21 (±0.06) | 1.24 (±0.05) |
| M5 | Gly Trp His Arg Trp Trp Tyr | 1.84 (±0.06) | 0.97 (±0.06) | 1.26 (±0.04) |
| M6 | Gly Lys Phe Gly Ser Ala Ser | 1.81 (±0.11) | 1.04 (±0.05) | 1.38 (±0.12) |
| M7 | Leu Val Val Thr Thr Leu Ile | 1.80 (±0.08) | 0.89 (±0.04) | 1.69 (±0.15) |
| M8 | Gly Lys Leu Tyr Arg Tyr Asp | 1.75 (±0.05) | 0.98 (±0.03) | 1.65 (±0.13) |
| M9 | Ile Ser Val Trp Leu Val Ala | 1.67 (±0.05) | 0.94 (±0.09) | 0.97 (±0.05) |
| M10 | Ser Arg Val Leu Val Ser Cys | 1.64 (±0.06) | 1.06 (±0.02) | 2.23 (±0.22) |
| control | - | 1.34 (±0.04) | 0.89 (±0.11) | 1.63 (±0.05) |
| H1 | Thr Lys Leu Ser Pro Leu Ile | 1.44 (±0.11) | ND | 1.23 (±0.06) |
| H2 | Ala Leu Pro Val Val Val Ile | 1.39 (±0.05) | ND | 1.49 (±0.06) |
| H3 | Gly Ala Val Asp Val Leu Val | 1.37 (±0.13) | ND | 1.24 (±0.12) |
| H4 | Asp Tyr Val Asp Cys Pro Arg | 1.35 (±0.06) | ND | 1.44 (±0.04) |
| H5 | Phe Leu Cys Pro His Asp Ser | 1.33 (±0.08) | ND | 1.18 (±0.02) |
| H6 | Glu Leu Phe Val Pro Tyr Cys | 1.23 (±0.07) | ND | ND |
| H7 | Lys Ala Ser Leu Asp Pro Leu | 1.21 (±0.09) | ND | ND |
| H8 | Gly Ala Phe Met Val Asp Ser | 1.13 (±0.07) | ND | ND |
| H9 | Asn Ala Ile Ala Ile Arg Arg | 1.12 (±0.15) | ND | 1.56 (±0.11) |
| H10 | Asn Val Leu Ala Phe Lys Gly | 1.11 (±0.10) | ND | 1.26 (±0.04) |
| control | - | 0.96 (±0.11) | ND | 1.32 (±0.05) |
The activity is shown as a ratio of marker gene expression measured in the absence and presence of the corresponding compound. The plasmids without 5' extensions in the marker gene coding ORFs, p177-NotI, pPOTZ-HindIII and pETGFP, were used as controls for β-lactamase, β-galactosidase and GFP activity respectively. Amino acid sequences of the peptides encoded by the randomized part of the plasmid are shown. Standard errors are indicated. ND - not determined.
Number of amino acids in the randomized part of the sequences (Table 1), analyzed according to the chemical used in selection.
| erythromycin | chloramphenicol | troleandomycin | meta-toluate | HSL | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Amino acid | Total number | Sequences | Total number | Sequences | Total number | Sequences | Total number | Sequences | Total number | Sequences |
| A | 3 | 3 | 4 | 4 | 5 | 3 | 5 | 4 | 7 | 6 |
| C | 1 | 1 | 5 | 4 | 3 | 3 | 2 | 2 | 3 | 3 |
| D | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 6 | 5 |
| E | - | - | 4 | 4 | 5 | 5 | 1 | 1 | 1 | 1 |
| F | 3 | 3 | 5 | 4 | 3 | 3 | 3 | 2 | 4 | 3 |
| G | 9 | 5 | 10 | 7 | 7 | 3 | 5 | 4 | 3 | 3 |
| H | 3 | 3 | - | - | 2 | 2 | 1 | 1 | 1 | 1 |
| I | 6 | 5 | 2 | 2 | 5 | 4 | 4 | 4 | 4 | 3 |
| K | - | - | 2 | 1 | - | - | 5 | 5 | 3 | 2 |
| L | 13 | 8 | 1 | 1 | 5 | 3 | 8 | 6 | 9 | 7 |
| M | - | - | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 1 |
| N | 3 | 3 | 2 | 2 | 1 | 1 | - | - | 2 | 2 |
| P | - | - | 3 | 2 | 1 | 1 | - | - | 6 | 6 |
| Q | - | - | 2 | 2 | 1 | 1 | 1 | 1 | - | - |
| R | 5 | 5 | 7 | 4 | 13 | 8 | 6 | 5 | 3 | 2 |
| S | 10 | 7 | 6 | 5 | 9 | 9 | 6 | 4 | 4 | 4 |
| T | 1 | 1 | 3 | 3 | - | - | 3 | 2 | 1 | 1 |
| V | 8 | 7 | 8 | 6 | 4 | 3 | 6 | 3 | 10 | 6 |
| W | 2 | 2 | 1 | 1 | 1 | 1 | 5 | 3 | - | - |
| Y | 2 | 2 | 2 | 2 | 1 | 1 | 6 | 4 | 2 | 2 |
"Total number" indicates the total number of amino acids in the sequence group; "Sequences" indicates the number of sequences containing the particular amino acid.
Figure 1The effects of mRNA structure on the activities of the constructs. The activity of β-galactosidase fused with original sequences E1, E5 and C7 was compared to the activities of variants containing synonymous substitutions (marked with asterisks). The nucleotide sequences of the constructs are shown. The expression of β-galactosidase marker protein was measured 3 h after induction with IPTG in the absence and presence of the corresponding antibiotic. The activity of each construct is shown as a ratio of Miller units measured in the absence and presence of antibiotic.
Figure 2The effects of amino acid substitutions in the E4 sequence. Amino acid substitutions in mutants are marked in capital letters. All sequence variants were tested as β-galactosidase fusions. The expression of β-galactosidase marker protein was measured 3 h after induction with IPTG in the absence and presence of the corresponding antibiotic. The activity of each construct is shown as a ratio of Miller units measured in the absence and presence of antibiotic.
Figure 3Cross-responses of the sequences to different compounds as measured in the β-galactosidase reporter system. The sequences originally selected on erythromycin (A), chloramphenicol (B), troleandomycin (C) and meta-toluate (D) were tested. Constructs containing ErmC leader peptide and a mutant of E4 peptide (Mut8, Figure 2) were included. The expression of β-galactosidase marker protein was measured 3 h after induction with IPTG in the absence and presence of compound (E-erythromycin, C-chloramphenicol, T-troleandomycin, M-meta-toluate). The activity of each construct is shown as a ratio of Miller units measured in the absence and presence of the compound. Gray bars indicate the activity in the presence of the compound which was used for selecting the sequence.
Figure 4Cross-responses of the sequences to different compounds as measured using the GFP reporter system. The sequences originally selected on erythromycin (A), chloramphenicol (B), troleandomycin (C), meta-toluate (D) and homoserine lactone (E) were tested. The expression of GFP marker protein was measured 3 h after induction with IPTG in the absence and presence of the compound (E-erythromycin, C-chloramphenicol, T-troleandomycin, M-meta-toluate, H-homoserine lactone). The activity of each construct is shown as a ratio of GFP fluorescence measured in the absence and presence of the compound. Gray bars indicate the activity in the presence of the compound which was used for selecting the sequence.